IMNM at a glance
Immunome Inc. (IMNM, SEC CIK 1472012) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on October 5, 2026 and Form 4 insider filings as recently as September 15, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.
- For the fiscal year ended December 31, 2025 (FY2025), Immunome Inc. (IMNM) reported revenue of $6.9 million (down 23.2% from FY2024) and a net loss of $212.4 million. Diluted EPS was -$2.43.
- The most recent insider open-market sale reported on Form 4 was by Higgins Jack on September 11, 2026 of 13,200 shares at $25.32 per share.
- In the last 90 days, IMNM insiders reported 0 open-market purchases ($0) and 7 open-market sales ($5.7M) on Form 4, a net sale of $5.7M.
Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).
- Revenue · FY2025
- $6.9M
- −23.2% vs prior year
- Insiders · 90 days
- 0 buys · 7 sells
- Net −$5.7M
- Latest 8-K
- Aug 11, 2026
- Item 2.02
AI 10-K Annual Report Analysis
Latest 10-K, fiscal year ended Dec 31, 2025
Business Overview
- Core business model: Development and commercialization of first- and best-in-class targeted oncology therapies with focus on antibody-drug conjugates (ADCs) and radioligand therapies (RLTs)
- New emphasis on varegacestat for desmoid tumors with positive Phase 3 results and planned NDA submission Q2 2026
- Strategic shift to advancing innovative pipeline including IM-1021 (ROR1 ADC in Phase 1) and IM-3050 (FAP-targeted RLT with IND clearance in April 2025)
- Pipeline breadth: 3 clinical and 3 preclinical assets; positive Phase 3 topline for varegacestat showing 84% PFS risk reduction (HR=0.16, p<0.0001)
- Noteworthy: Acquisition of varegacestat from Ayala Pharmaceuticals in March 2024 and fastest pivotal study hazard ratio reported in desmoid tumor population
Risk Factors
- Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises
- Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience
- Board audit committee oversight of cybersecurity risk management and incident reporting, with escalation protocols for material cyber threats
Management Discussion & Analysis
- Collaboration revenue $6.9M, down $2.1M YoY from $9.0M, ceasing after July 2025 termination
- Operating margin improvement: operating loss $224.1M vs $305.8M, R&D expenses up to $177.3M vs $129.5M, G&A $43.8M vs $33.0M
- Best segment: Varegacestat R&D $52.4M, up $24.4M YoY; Worst segment: IM-1021 R&D $11.0M, down $13.1M YoY
- Cash flow 2025: Operating cash use $190.9M vs $110.8M; Financing inflows $640.4M (public offerings and ATM); Capex $9.7M and IPR&D purchase $6.2M
- Outlook: NDA submission for varegacestat Q2 2026; Increased R&D and G&A expected for clinical advancement and commercialization; Additional financing likely needed beyond 12 months
AI summary of the IMNM 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K
AI 10-Q Quarterly Report Analysis
Latest 10-Q, quarter ended Jun 30, 2026
Risk Factors
- NDA review risk: Varegacestat application accepted with FDA PDUFA target action date of April 28, 2027
- Regulatory compliance risk: FDA may require additional trials, narrower labeling, REMS, or post-marketing studies
- Clinical execution risk: Three early-stage assets remain in Phase 1, including IM-1021, IM-1617, and IM-3050
- Liquidity risk: Cash, cash equivalents, and marketable securities expected to fund operations for at least 12 months
- Financial loss risk: Accumulated deficit reached $855.1 million as of June 30, 2026
AI summary of the IMNM 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K
AI 8-K Current Report Analysis
The most recent material events, by 8-K item
Item 2.02: Results of Operations and Financial Condition
- Q2 2026 results covered quarter ended June 30, 2026
- Business update and financial results provided in Exhibit 99.1
Item EX-99.1: Item EX-99.1
- FDA accepted varegacestat NDA; PDUFA decision target April 28, 2027, creating a defined regulatory catalyst
- Phase 3 RINGSIDE showed 84% lower progression-or-death risk and 56% objective response rate versus 9% placebo
Item 5.07: Submission of Matters to a Vote of Security Holders
- Stockholders elected James Boylan, Sandra Swain, M.D., and Philip Wagenheim as Class III directors through 2029
- Boylan received 70,209,570 votes for versus 22,171,996 withheld, signaling notable shareholder opposition
AI summaries of IMNM 8-K current reports filed with the SEC. What 8-K item codes mean
SignalX for IMNM
Don't miss the next IMNM filing
- Alerts as it files. A push when IMNM files an 8-K or an insider trades.
- Fund moves. Which tracked funds opened, added or cut IMNM, by share count.
- Ask anything. An AI agent that reads every IMNM filing and answers with sources.
IMNM alerts on your phone. Follow it in the SignalX Android app.
Recent Insider Transactions (Form 4)
Latest reported trades by officers, directors and 10% owners
| Insider | Type | Date | Shares | Price |
|---|---|---|---|---|
| Higgins Jack | M | Sep 11, 2026 | 18,000 | $1.35 |
| Higgins Jack | Sell | Sep 11, 2026 | 13,200 | $25.32 |
| Higgins Jack | G | Sep 11, 2026 | 8,800 | - |
| Higgins Jack | M | Sep 11, 2026 | 18,000 | - |
| Barchas Isaac | Sell | Aug 12, 2026 | 11,048 | $27.25 |
| Barchas Isaac | Sell | Aug 11, 2026 | 62,291 | $26.23 |
| Barchas Isaac | Sell | Aug 10, 2026 | 10,125 | $26.07 |
| Barchas Isaac | Sell | Aug 7, 2026 | 15,248 | $26.06 |
Financial SummaryXBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Profitability | |||
| Revenue | - | $9.0M | $6.9M |
| Operating Income | -$109.5M | -$305.8M | -$224.1M |
| Net Income | -$106.8M | -$293.0M | -$212.4M |
| Op. Margin | - | -3382.4% | -3228.8% |
| Net Margin | - | -3240.4% | -3060.0% |
| Balance Sheet | |||
| Total Assets | - | $240.2M | $683.2M |
| Equity | - | $181.2M | $634.3M |
| ROE | - | -161.7% | -33.5% |
| Per Share | |||
| EPS | $-5.38 | $-5.00 | $-2.43 |
| Cash Flow | |||
| Operating CF | -$7.6M | -$110.8M | -$190.9M |
| CapEx | - | $7.2M | $9.7M |
Source: XBRL data in Immunome Inc. (IMNM)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →
IMNM filing archive
AI analysis pages for each 10-K, 10-Q and 8-K
10-K annual reports
10-Q quarterly reports
8-K current reports
Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4
| Form | Filing date | Period | Analysis | SEC |
|---|---|---|---|---|
| 8-K | Oct 5, 2026 | - | - | - |
| 4 | Sep 15, 2026 | - | - | - |
| 4 | Aug 12, 2026 | - | - | - |
| 8-K | Aug 11, 2026 | - | Analysis | - |
| 10-Q | Aug 11, 2026 | Jun 30, 2026 | Analysis | |
| 4 | Aug 10, 2026 | - | - | - |
| 4 | Aug 6, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 27, 2026 | - | - | - |
| 4 | Jul 9, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 7, 2026 | - | - | - |
| 4 | Jul 2, 2026 | - | - | - |
| 4 | Jun 29, 2026 | - | - | - |
| 4 | Jun 17, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 4 | Jun 12, 2026 | - | - | - |
| 8-K | Jun 12, 2026 | - | Analysis | - |
| 4 | Jun 12, 2026 | - | - | - |
Related Health Care companies
- AARD · Aardvark Therapeutics, Inc.Pharmaceutical Preparations
- ABT · Abbott LaboratoriesPharmaceutical Preparations
- ABBV · AbbVie IncPharmaceutical Preparations
- ABEO · ABEONA THERAPEUTICS INC.Pharmaceutical Preparations
- ACAD · ACADIA PHARMACEUTICALS INCPharmaceutical Preparations
- ACRS · Aclaris Therapeutics, Inc.Pharmaceutical Preparations
- ACTU · ACTUATE THERAPEUTICS, INC.Pharmaceutical Preparations
- ADCT · ADC Therapeutics SAPharmaceutical Preparations
IMNM SEC filings: frequently asked questions
Are IMNM insiders buying or selling?
In the last 90 days, Immunome Inc. (IMNM) officers, directors and 10% owners reported no open-market purchases and 7 open-market sales worth $5.7 million by 3 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.
What was IMNM's revenue in fiscal year 2025?
For the fiscal year ended December 31, 2025 (FY2025), Immunome Inc. (IMNM) reported revenue of $6.9 million (down 23.2% from FY2024) and a net loss of $212.4 million. Diluted EPS was -$2.43. The figures come from the XBRL data in the 10-K.
What are the main risks in IMNM's latest 10-K?
In the 10-K filed March 3, 2026, Immunome Inc. (IMNM) flagged: Cybersecurity risk with potential regulatory fines, litigation, operational disruption, and reputational harm from IT system compromises. Key-person dependency on three senior IT officers managing cybersecurity, including Head of IT and Senior Director with 30+ years biotech experience. (AI summary of the Risk Factors section.)
What did IMNM report in its latest 8-K?
Immunome Inc. (IMNM) filed an 8-K on August 11, 2026 reporting Item 2.02 (Results of Operations and Financial Condition). Q2 2026 results covered quarter ended June 30, 2026.
What are the latest IMNM SEC filings?
Immunome Inc. (IMNM) filed its latest 10-K annual report on March 3, 2026, a 10-Q quarterly report on August 11, 2026, an 8-K current report on October 5, 2026 and a Form 4 insider filing on September 15, 2026.
What is IMNM's SEC CIK number?
Immunome Inc. (IMNM)'s SEC Central Index Key (CIK) is 1472012. EDGAR lists every IMNM filing under that number.
Ask anything about IMNM
The research agent reads IMNM's filings, financials, insider trades and 13F holders, then answers with sources.